Toggle light / dark theme

LinkedIn, the Microsoft-owned social platform, has made a name for itself primarily as a platform for people looking to network and pick up knowledge for professional purposes, and for recruitment — a business that now has more 1 billion users. Now, to boost the time people are spending on the platform, the company is breaking into a totally new area: gaming.

TechCrunch has learned and confirmed that LinkedIn is working on a new games experience. It will be doing so by tapping into the same wave of puzzle-mania that helped simple games like Wordle find viral success and millions of players. Three early efforts are games called “Queens”, “Inference” and “Crossclimb.”

App researchers have started to find code that points to the work LinkedIn is doing. One of them, Nima Owji, said that one idea LinkedIn appears to be experimenting with involves player scores being organised by places of work, with companies getting “ranked” by those scores.

We use two 1D quasicondensates in a double potential well to realize a bosonic Josephson junction, a microscopic system that gives rise to interesting quantum phenomena resulting from the interplay of quantum tunneling and interaction. The multimode characteristics within the quasicondensates make the system suitable as a quantum field simulator. To prepare quantum states, we split a single condensate into two and, consequently, we witness the dynamical evolution of quantum fluctuations in the relative degree of freedom between the two split condensates. We demonstrate how to use these dynamics to effectively prepare more strongly correlated quantum states and how those influence spatial phase coherence.

Our work introduces innovative methods for engineering correlations and entanglement in the external degree of freedom of interacting many-body systems. It is a leap forward in understanding and harnessing quantum correlations, paving the way for exciting possibilities in quantum simulation research.

They treated three patients with recurrent glioblastoma using a variant of an existing CAR-T therapy, adding additional antibodies to the treatment — and the results were truly astounding.

According to the paper published in The New England Journal of Medicine, one patient saw their tumor decrease in size by 18.5% two days after the treatment, and by day 69, the tumor had decreased by 60.7%, while another saw their ‘tumor regress rapidly’, according to Mass General Brigham.

After the third patient was treated, an MRI showed that a single infusion had led to a ‘near-complete tumor regression’ in just five days.